3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
71
Lung Neoplasms
32
Triple Negative Breast Neoplasms
23
Breast Neoplasms
19
Small Cell Lung Carcinoma
15
Ovarian Neoplasms
15
Squamous Cell Carcinoma of Head and Neck
13
Endometrial Neoplasms
13
Neoplasms
12
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Fallopian Tube Neoplasms
10
Neoplasm Metastasis
9
Colorectal Neoplasms
6
Urinary Bladder Neoplasms
5
Carcinoma
5
Adenocarcinoma of Lung
5
Esophageal Neoplasms
4
Uterine Cervical Neoplasms
3
Pathologic Complete Response
3
Pancreatic Neoplasms
3
Oropharyngeal Neoplasms
3
Mesothelioma
3
Melanoma
3
Lung Diseases
3
Head and Neck Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Central Nervous System Neoplasms
3
Uterine Neoplasms
2
Thoracic Neoplasms
2
Sarcoma
2
Interventions
Carboplatin
2
repotrectinib
1
pembrolizumab
1
durvalumab
1
Pemetrexed
1
Cisplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Respiratory Tract Diseases
×
Carboplatin
×
30 days
×
Clear all
NCT06119581
2026-06-03
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled
NCT07279935
2026-06-01
REVIVE
AstraZeneca
Phase 4
Recruiting
100 enrolled